Pulse Biosciences (NASDAQ:PLSE) Sees Large Volume Increase – Still a Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) saw unusually-high trading volume on Monday . Approximately 248,495 shares were traded during trading, a decline of 13% from the previous session’s volume of 284,261 shares.The stock last traded at $21.1950 and had previously closed at $20.75.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on PLSE shares. Mizuho set a $30.00 price objective on Pulse Biosciences in a report on Friday, February 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $26.00.

Pulse Biosciences Trading Up 5.6%

The stock has a market capitalization of $1.71 billion, a PE ratio of -22.35 and a beta of 1.77. The business’s 50-day moving average is $14.97 and its two-hundred day moving average is $15.66.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its holdings in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Pulse Biosciences by 44.0% during the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after purchasing an additional 1,372 shares in the last quarter. KLP Kapitalforvaltning AS boosted its stake in shares of Pulse Biosciences by 136.0% in the third quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after purchasing an additional 3,400 shares during the period. Finally, AlphaQuest LLC grew its holdings in Pulse Biosciences by 184.5% during the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after purchasing an additional 5,748 shares in the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.